本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Immix Biopharma, Inc

2.09
-0.0550-2.56%
盤後2.090.00000.00%16:05 EDT
成交量:4.75萬
成交額:10.08萬
市值:5,793.92萬
市盈率:-2.74
高:2.22
開:2.10
低:2.04
收:2.15
資料載入中...
2022/02/11

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/09

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/01/25

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2022/01/19

重要事件披露

8-K - Current report
2022/01/12

重要事件披露

8-K - Current report
2022/01/03

重要事件披露

8-K - Current report
2021/12/28

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/12/20

重要事件披露

8-K - Current report
2021/12/13

SEC問詢函

CORRESP [Cover] - Correspondence
2021/12/13

SEC問詢函

CORRESP [Cover] - Correspondence
2021/12/01

[補充]招股説明書

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2021/11/04

[修訂]招股説明書

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
2021/10/28

[修訂]招股説明書

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
2021/10/15

SEC問詢函

CORRESP [Cover] - Correspondence
2021/10/15

[修訂]招股説明書

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
2021/10/06

SEC問詢函

CORRESP [Cover] - Correspondence
2021/10/06

[修訂]招股説明書

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
2021/09/17

招股説明書

S-1 - General form for registration of securities under the Securities Act of 1933
2021/09/16

SEC問詢函

CORRESP [Cover] - Correspondence